Microbiota-A Rescuing Modulator in Children Struggling with Functional Constipation

Nicoleta Ana Tomșa1, Lorena Elena Meliț2, Teodora Popescu1

  • 1Doctoral School of Medicine and Pharmacy, "George Emil Palade" University of Medicine, Pharmacy, Science and Technology of Targu Mures, Gheorghe Marinescu Street, No. 38, 540136 Targu Mures, Romania.

Microorganisms
|July 30, 2025
PubMed

Insights

Functional constipation in children is linked to gut microbiota changes. Probiotics show promise in improving symptoms by restoring beneficial bacteria and reducing inflammation, though more research is needed for standard use.

Area of Science:

  • Pediatric Gastroenterology
  • Microbiology
  • Immunology

Background:

  • Functional constipation (FC) affects 30% of children, with 95% of cases being functional.
  • FC involves alterations in gut peristalsis, influenced by the immune system, nervous system, bile acid metabolism, and gut microbiota.

Purpose of the Study:

  • To review the role of gut microbiota in pediatric constipation.
  • To assess the efficacy of probiotics in managing constipation in children.

Main Methods:

  • Literature review of studies on gut microbiota and probiotics in pediatric functional constipation.
  • Analysis of microbiota composition changes in chronic FC.
  • Evaluation of probiotic mechanisms of action.

Main Results:

  • Altered gut microbiota in chronic FC shows increased Bacteroidetes, Enterobacteriaceae, and Firmicutes, with decreased Prevotella, Bifidobacteria, Faecalibacterium prausnitzii, and Clostridium leptum.
  • Probiotics like Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium animalis subsp. lactis XLTG11 may increase defecation frequency and reduce fecal incontinence and abdominal pain.
  • Lactobacilli enhance gut motility and stool moisture through organic acid production.

Conclusions:

  • Gut microbiota alterations are evident in pediatric functional constipation.
  • Specific probiotic strains demonstrate potential benefits for constipation symptoms.
  • Study heterogeneity currently limits the standardization of probiotics in pediatric constipation management.

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
336
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents01:20

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents

Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
319
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
299
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
541
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
203
Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
390